FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MURPHY ANDREW J
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/11/2019 

3. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [(REGN)]
(Last)        (First)        (Middle)

777 OLD SAW MILL RIVER ROAD
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP Research /
(Street)

TARRYTOWN, NY 10591      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 45326 (1)D  
Common Stock 4212 I By 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy)  (2)12/14/2020 Common Stock 3264 $30.63 D  
Incentive Stock Option (right to buy)  (2)12/16/2021 Common Stock 1921 $52.03 D  
Non-Qualified Stock Option (right to buy)  (2)12/14/2020 Common Stock 26736 $30.63 D  
Non-Qualified Stock Option (right to buy)  (2)12/16/2021 Common Stock 33079 $52.03 D  
Non-Qualified Stock Option (right to buy)  (3)12/14/2022 Common Stock 40000 $179.13 D  
Non-Qualified Stock Option (right to buy)  (3)12/13/2023 Common Stock 40000 $270.43 D  
Non-Qualified Stock Option (right to buy)  (3)12/16/2024 Common Stock 40000 $399.66 D  
Non-Qualified Stock Option (right to buy)  (3)12/16/2025 Common Stock 35000 $555.67 D  
Non-Qualified Stock Option (right to buy)  (3)12/16/2026 Common Stock 34000 $381.92 D  
Non-Qualified Stock Option (right to buy)  (3)12/12/2027 Common Stock 50000 $378.98 D  
Non-Qualified Stock Option (right to buy)  (3)12/12/2028 Common Stock 25000 $381.40 D  

Explanation of Responses:
(1) Includes an award of 15,000 shares of restricted stock that vests in its entirety on December 12, 2023.
(2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. The stock option award expires on the ten-year anniversary of the date of grant.
(3) The stock option award vests in four equal annual installments, commencing one year after the date of grant. The stock option award expires on the ten-year anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
MURPHY ANDREW J
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP Research

Signatures
/s/Andrew Murphy12/13/2019
**Signature of Reporting PersonDate

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Regeneron Pharmaceuticals Charts.